drugset / Trial / NCT07142811
A Study to Evaluate Tobevibart+Elebsiran Versus Bulevirtide in Chronic HDV Infection
RandomizedParallel-groupOpen-labelTreatment
Summary
A Study to Evaluate Tobevibart+Elebsiran versus Bulevirtide in Chronic HDV Infection
Timeline
- Start
- 2025-08-05
- Primary completion
- 2026-11
- Completion
- 2030-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bulevirtide | Protein / enzyme biologic | — | Subcutaneous |
| Subject | Tobevibart | Monoclonal antibody | — | Subcutaneous |
| Subject | VIR-2218 | Small interfering RNA (siRNA) | — | Subcutaneous |